Cargando…
CDK 4/6 inhibitors combined with radiotherapy: A review of literature
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and abemaciclib were granted approval by the European Medicines Agency (EMA) between 2017 and 2018. They are currently prescribed in combination with hormone therapy to treat hormone receptor positive, HER2 negative...
Autores principales: | Bosacki, Claire, Bouleftour, Wafa, Sotton, Sandrine, Vallard, Alexis, Daguenet, Elisabeth, Ouaz, Hamza, Cojoracu, Iohel, Moslemi, Dariush, Molekzadehmoghani, Mona, Magné, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724290/ https://www.ncbi.nlm.nih.gov/pubmed/33319074 http://dx.doi.org/10.1016/j.ctro.2020.11.010 |
Ejemplares similares
-
Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators
por: Moghani, Mona Malekzadeh, et al.
Publicado: (2022) -
Focus on the expected quality of reporting in SBRT/radiosurgery prospective studies: how far have we come in 30 years?
por: Vial, Nicolas, et al.
Publicado: (2021) -
Recove® burn ointment for managing acute radiodermatitis in patients with breast cancer: A double blind randomized controlled trial
por: Abbaszade Marzbali, Nargeuss, et al.
Publicado: (2022) -
Radiation-induced bystander and abscopal effects: important lessons from preclinical models
por: Daguenet, Elisabeth, et al.
Publicado: (2020) -
Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis
por: Trone, Jane-Chloe, et al.
Publicado: (2020)